An acute or chronic, localized or disseminated infection by Cryptococcus neoformans. Sites of involvement include the lungs, central nervous system and meninges, skin, and visceral organs.--2004
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
The documentation on cryptococcosis is limited primarily due to its variable presentation and the fact that it affects a smaller population, particularly immunocompromised individuals. This rarity makes large-scale clinical studies challenging, leading to gaps in our understanding of its genetic basis and long-term outcomes. Ongoing research aims to clarify these aspects and improve management strategies.
Key clinical features of cryptococcosis include fever and cough, both occurring in 30-79% of cases, often alongside immunodeficiency. Other manifestations can include meningitis, hydrocephalus, and various eye abnormalities, although these are less common, affecting 5-29% of patients. The disease can lead to significant complications, especially in individuals with weakened immune systems.
To navigate your condition, consider consulting an infectious disease specialist with experience in fungal infections, particularly cryptococcosis. While there are currently no patient organizations specifically for cryptococcosis, you can find general resources through the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. Additionally, inquire about participating in clinical trials, as they may provide access to new treatments and contribute to ongoing research efforts.
Currently, there are two orphan drugs designated for cryptococcosis: Encochleated oral Amphotericin B suspension and fosmanogepix, which are in development. Additionally, there are seven active clinical trials investigating various treatment approaches for cryptococcosis. For more information on these trials, you can visit ClinicalTrials.gov and search for cryptococcosis.
Actionable guidance for navigating care for cryptococcosis
To navigate your condition, consider consulting an infectious disease specialist with experience in fungal infections, particularly cryptococcosis. While there are currently no patient organizations specifically for cryptococcosis, you can find general resources through the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. Additionally, inquire about participating in clinical trials, as they may provide access to new treatments and contribute to ongoing research efforts.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning cryptococcosis
Updated Jan 23, 2026
A case report details intralobar pulmonary sequestration occurring alongside pulmonary cryptococcosis, contributing to the understanding of these rare conditions. The literature review provides insights into the clinical implications and management strategies for affected patients.
Cases of recreational water illnesses, particularly cryptosporidiosis, are on the rise, posing a significant public health challenge. The chlorine-resistant parasite is expected to become an even bigger concern in the future.